[go: up one dir, main page]

HK1201750A1 - 使用 激酶抑制劑的癌症治療 - Google Patents

使用 激酶抑制劑的癌症治療

Info

Publication number
HK1201750A1
HK1201750A1 HK15102376.3A HK15102376A HK1201750A1 HK 1201750 A1 HK1201750 A1 HK 1201750A1 HK 15102376 A HK15102376 A HK 15102376A HK 1201750 A1 HK1201750 A1 HK 1201750A1
Authority
HK
Hong Kong
Prior art keywords
tor
cancer
treatment
kinase inhibitors
tor kinase
Prior art date
Application number
HK15102376.3A
Other languages
English (en)
Inventor
Shuichan Xu
Kristen Mae Hege
Heather Raymon
Lilly Loraine Wong
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of HK1201750A1 publication Critical patent/HK1201750A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102376.3A 2012-03-15 2015-03-09 使用 激酶抑制劑的癌症治療 HK1201750A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US201261715323P 2012-10-18 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1201750A1 true HK1201750A1 (zh) 2015-09-11

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102376.3A HK1201750A1 (zh) 2012-03-15 2015-03-09 使用 激酶抑制劑的癌症治療

Country Status (22)

Country Link
US (1) US20130245026A1 (zh)
EP (1) EP2825170B1 (zh)
JP (3) JP2015510891A (zh)
KR (3) KR20210071101A (zh)
CN (2) CN104519885A (zh)
AU (1) AU2013203153B2 (zh)
BR (1) BR112014022703A2 (zh)
CA (1) CA2866872A1 (zh)
EA (1) EA028414B1 (zh)
ES (1) ES2677874T3 (zh)
HK (1) HK1201750A1 (zh)
IL (1) IL234602B (zh)
MX (1) MX360878B (zh)
MY (1) MY174022A (zh)
NI (1) NI201400111A (zh)
NZ (1) NZ628416A (zh)
PH (1) PH12014502029B1 (zh)
SG (1) SG11201405707XA (zh)
TW (1) TWI583385B (zh)
UA (1) UA114315C2 (zh)
WO (1) WO2013138557A1 (zh)
ZA (1) ZA201406706B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138557A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP3202403A1 (en) 2013-01-16 2017-08-09 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR102242505B1 (ko) 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
JP6382947B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 前立腺癌を治療するためのジヒドロピラジノ−ピラジン化合物及びアンドロゲン受容体アンタゴニストを含む組合せ療法
PE20160041A1 (es) 2013-04-17 2016-01-28 Signal Pharm Llc FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986297A1 (en) * 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
TWI656875B (zh) 2013-04-17 2019-04-21 美商標誌製藥公司 藉二氫吡并吡治療癌症
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
BRPI0717773A2 (pt) * 2006-10-19 2013-11-05 Signal Pharm Llc Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
WO2013138557A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors

Also Published As

Publication number Publication date
IL234602A0 (en) 2014-11-30
PH12014502029A1 (en) 2014-11-24
US20130245026A1 (en) 2013-09-19
EP2825170A1 (en) 2015-01-21
EP2825170B1 (en) 2018-05-09
WO2013138557A1 (en) 2013-09-19
CN108992446A (zh) 2018-12-14
SG11201405707XA (en) 2014-10-30
KR20210071101A (ko) 2021-06-15
ES2677874T3 (es) 2018-08-07
NI201400111A (es) 2015-01-15
TW201343168A (zh) 2013-11-01
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
BR112014022703A2 (pt) 2021-05-04
EA028414B1 (ru) 2017-11-30
KR102122617B1 (ko) 2020-06-12
CN104519885A (zh) 2015-04-15
KR20200070416A (ko) 2020-06-17
ZA201406706B (en) 2016-05-25
MY174022A (en) 2020-03-04
JP2019108368A (ja) 2019-07-04
MX360878B (es) 2018-11-21
CA2866872A1 (en) 2013-09-19
KR20140138927A (ko) 2014-12-04
MX2014011077A (es) 2014-10-14
UA114315C2 (uk) 2017-05-25
JP2021102637A (ja) 2021-07-15
TWI583385B (zh) 2017-05-21
JP2015510891A (ja) 2015-04-13
EA201491699A1 (ru) 2015-02-27
AU2013203153B2 (en) 2015-09-03
NZ628416A (en) 2016-04-29
IL234602B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HK1243919A1 (zh) 利用tor激酶抑制劑治療癌症
HK1202247A1 (zh) 激酶抑制劑治療癌症
HK1201750A1 (zh) 使用 激酶抑制劑的癌症治療
HK1220640A1 (zh) 用谷氨醯胺酶的雜環抑制劑治療癌症
HK1201753A1 (zh) 使用 激酶抑制劑的癌症治療
HK1214128A1 (zh) 癌症的治療
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
HK1204956A1 (zh) 癌症治療
HK1205254A1 (zh) 治療癌症的方法
GB201217892D0 (en) Treatment of cancer
HK1205500A1 (zh) 用於癌症治療的激酶抑制劑
GB201217890D0 (en) Treatment of cancer
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors
GB201208296D0 (en) Treatment of cancer